Solid Biosciences Inc. announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne). As part of the organizational changes, the company will reduce its work force by approximately one third.

In conjunction, Chief Operating Officer Alvaro Amorrortu, M.B.A. and Chief Medical Officer Jorge Quiroz, M.D., M.B.A. will depart the company but will continue as advisors to Solid. The corporate changes implemented will result in a reduction in corporate expenses and, based on the company's current operating plans, are expected to extend the cash runway into 2021.